Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Reductions in mortality for lung, female breast, prostate, and colorectal cancers accounted for 60 to 80 percent of the total decrease in all cancer deaths since the early 1990s.  
  • A 2002 study found that image-guided percutaneous needle biopsies are between 3 and 7 times more cost-effective than open surgical biopsies, require a shorter procedure time, result in fewer infections,…  
  • Widespread use of telomerase inhibitors could result in a 50% cure rate and a 25% prolongation of life for 50% of eligible patients with solid tumors.  
  • According to the Pharmaceutical Research and Manufacturers of America, researchers are currently working on 646 medicines for cancer. All are either in clinical trials or under FDA review. …  
  • A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in…